Code extended to cover all interactions with healthcare professionals, medical institutions, and patient organizations Code provides effective framework for ethical business practices International patient organization welcomes new rules IFPMA encourages equally high standards across healthcare sector 1 March 2012, Geneva – Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced an expansion of...
Read moreDonations focused on meeting new WHO targets for maximum impact against NTDs Builds on industry’s long‐standing record of innovating treatments for neglected tropical diseases 30 January 2012, Geneva – Today the research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases (NTDs). Averaging 1.4 billion treatments annually, the donations build upon companies’ existing medicines donation programmes which already reach millions of people around...
Read more130th Executive Board of the World Health Organization IFPMA Statement under agenda item 6.11, “Elimination of Schistomiasis” Remarks by Mario Ottiglio, Associate Director, Global Health Policy and Public Affairs Mr. Chairman, Madam Director General, distinguished members of the Executive Board, Excellencies, ladies and gentlemen, Thank you for the opportunity to input on the important discussions...
Read moreVaccine supply data from 157 countries shows that global vaccination levels remain low; while policy measures that directly impact patients are linked to higher levels of Influenza Vaccination. Two studies being published this week in peer-reviewed journals look at global vaccination policies and use global vaccination provision data that had not been previously available. The...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) welcomes the decision taken at the Asia-Pacific Economic Cooperation CEO Summit to endorse “The Mexico City Principles for Voluntary Codes of Business Ethics in the Biopharmaceutical Sector”, often referred to as the “Mexico City Principles”. These principles are fully aligned with the IFPMA’s global Code of...
Read moreIFPMA, the body representing the global research-based pharmaceutical industry, welcomes the creation of WIPO Re:Search, a new voluntary database for sharing intellectual property for R&D on medicines and vaccines for tuberculosis, malaria and neglected tropical diseases. WIPO Re:Search was launched today in Geneva by the World Intellectual Property Organisation (WIPO), and was followed by a...
Read moreA report “Evidence on Access to Essential Medicines for the Treatment of HIV/AIDS 1 The report funded by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) provides insights into what measures can substantially increase ART coverage levels to over 80%. The report studied seven countries from across the globe (Botswana, Brazil, India, Mexico, Rwanda,...
Read moreTo coincide with the United Nations High-Level Meeting on NCDs, the research-based pharmaceutical industry today outlined the steps it is taking to address the rise of NCDs in the developing world. Building on its Framework for Action released earlier this year, the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) revealed the findings of the...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Biogen Idec Inc. has joined the Federation, thus bringing its membership up to 29 leading international companies and 44 national and regional industry associations. IFPMA Director General Eduardo Pisani said: “We are delighted to welcome Biogen Idec, a pioneering biotech company,...
Read moreThe International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is pleased to announce that Lundbeck and Innovative Pharma have joined the Federation, thus bringing its membership up to 28 leading international companies and 45 national and regional industry associations. Lundbeck is a global pharmaceutical company conducting research for the treatment of disorders in the central...
Read moreThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is pleased to announce the addition of a new member, Otsuka Pharmaceutical Co., Ltd. (Otsuka), a subsidiary of Otsuka Holdings Co., Ltd., Japan’s second largest research-based pharmaceutical company group. Otsuka’s accession to IFPMA was approved at the Council meeting held on June 22, 2011. “Otsuka’s participation...
Read moreThe research-based pharmaceutical industry launches today a Framework for Action to respond to concerns that cardiovascular disease, cancer, diabetes and chronic respiratory diseases are posing mounting threats to public health as well as public and private finances worldwide. The industry’s ten-point Framework scopes out specific areas of action to tackle non-communicable diseases (NCDs) including innovation,...
Read more